Grants by top pharma group to lightly regulated, politically active nonprofits dwarf its conventional campaign spending.
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
The Trump administration issued the final rule on association health plans, which supporters say will make coverage more affordable for some employees but led others to warn about “junk insurance.” Officials in California, aware of the state’s bad experience with such plans, are eager to avert their return.
Promises to control pharma prices threaten profits for Switzerland-based Novartis, which sells some of the costliest drugs in the world.
Hospitals and private investors have pumped vast sums of money into an advanced type of radiology that mostly spares healthy tissue while attacking tumors. The spending hasn’t always paid off — leading some facilities to close or, as in the case of a San Diego center last year, file for bankruptcy.
Denmark-based drugmaker Novo Nordisk has invested more in lobbying and doubled political donations since 2015.
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits, though their efforts fell short in California, which passed a drug transparency bill in 2017 despite massive opposition from drugmakers.
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
Months of reporting and rich hospital data portray life in the worst asthma hot spot in one of the worst asthma cities: Baltimore. The medical system knows how to help. But there’s no money in it.
The Affordable Care Act has increased the number of people with insurance, but shopping around for plans puts a burden on patients, especially this year.